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Abstract 
The mechanics of β-amyloid (Aβ) clearance by astrocytes has not been univocally described, with different 
mediators appearing to contribute to this process under different conditions. Our laboratory has 
demonstrated neuroprotective effects of astroglial subtype 3 metabotropic glutamate receptor (mGlu3R), 
which are dependent on the secreted form of the amyloid precursor protein (sAPPα) as well as on Aβ 
clearance; however, the mechanism underlying mGlu3R-induced Aβ uptake by astrocytes remains unclear. 
The present study shows that conditioned medium from mGlu3R-stimulated astrocytes increased Aβ uptake 
by naïve astrocytes through a mechanism dependent on sAPPα, since sAPPα depletion from conditioned 
medium inhibited Aβ phagocytosis. Concordantly, recombinant sAPPα also increased Aβ uptake. Since we 
show that both sAPPα and the mGlu3R agonist LY379268 increased expression of class-A scavenger 
receptor (SR-A) in astrocytes, we next determined whether SR-A mediates mGlu3R- or sAPPα-induced Aβ 
uptake by using astrocyte cultures derived from SR-A knockout mice. We found that the effects of LY379268 
as well as sAPPα on Aβ uptake were abolished in SR-A-deficient astrocytes, indicating a major role for this 
scavenger receptor in LY379268- and sAPPα-stimulated Aβ clearance by astrocytes. We also show results of 
coimmunoprecipitation and functional assays offering evidence of possible heterotrimerization of sAPPα 
with Aβ and SR-A which could allow Aβ to enter the astrocyte. In conclusion the present paper describes a 
novel pathway for Aβ clearance by astrocytes involving sAPPα as an enhancer of SR-A-dependent Aβ 
phagocytosis. 
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Defined abbreviations:  
mGlu3R: subtype 3 metabotropic glutamate receptor; APP: amyloid derived protein; sAPPα: secreted form 
of α-secretase-cleaved amyloid precursor protein; Aβ: β-amyloid; SR: scavenger receptors; SR-A: class-A 
scavenger receptor; AD: Alzheimer’s disease; GCM: glial conditioned medium; IP: immunoprecipitation; IB: 
immunoblot 
1. Introduction 
Metabotropic glutamate receptors (mGluR) belong to the superfamily of class III G-protein coupled 
receptors. Eight subtypes of mGluR have been described, classified into 3 groups. In Group II mGluR, the 
mGlu2R subtype is mainly presynaptic whereas the mGlu3R subtype is found preferentially in postsynaptic 
membranes and glial cells [1, 2]. Neuron-glia interaction has been widely shown to promote 
neuroprotection, in part through mechanisms involving group II mGluR activation [3].  
Alzheimer’s disease (AD) is the major cause of dementia for older people. Whereas the early-onset, 
hereditary form of AD is considered to derive from increased production of β-amyloid (Aβ) peptide from 
amyloid precursor protein (APP), the late-onset AD is thought to arise after failures in Aβ clearance 
mechanisms [4-6].  
At the cell surface, APP undergoes proteolysis by α-secretases that cleave it between Lys687 and Leu688 
thereby releasing a large, soluble ectodomain: sAPPα. Alternatively, APP can be cleaved by β-secretase to 
generate a fragment which -after further cleavage by γ-secretase- yields the Aβ peptide. We recently showed 
that mGlu3R activation by the agonist LY379268 promotes the non-amyloidogenic (or ‘alpha’) cleavage of 
APP in cultured astrocytes, leading to increased release of sAPPα [7], which has been demonstrated to exert 
neuroprotective action in several injury models and to improve cognition in AD and aging [8]. Furthermore, 
mGlu3R expression is diminished in hippocampal astrocytes from PDAPP-J20 mice [7], suggesting a role for 
this receptor in AD. In addition, our most recent results show that astrocyte-derived sAPPα protects 
hippocampal neurons from Aβ neurotoxicity [9]. Moreover, LY379268 is also able to increase Aβ uptake in 
both astrocytes and microglia, an effect that impacts positively on the survival of co-cultured neurons [9]. 
Nevertheless, how mGlu3R triggers Aβ engulfment by astrocytes is an unexplored research topic.  
Glial cells are the main scavengers of the brain, and Aβ is primarily internalized through receptor-mediated 
endocytosis [10]. Scavenger receptors (SR), Toll-like receptors, receptors for advanced glycation end 
products (RAGE), Fc receptors, and lipoprotein receptor-related proteins (LRP), among others, may be 
involved in Aβ uptake [10]. In microglia, we showed involvement of CD11b in the recognition/endocytosis of 
Aβ induced by Group II mGluR activation [9], whereas in astrocytes the underlying mechanism remains to be 
studied. Although we previously showed that LY379268 upregulates gene expression of SR CD36 in 
astrocytes [9], the literature points to class A SR (SR-A) as the central Aβ-interacting receptor in AD models. 
SR-A expression is reduced in the hippocampus of aged and APP/PS1 animals [11], and a triple transgenic 
APP/PS1/SR-A-/- mouse displays a reduced lifespan, reduced cognitive performance, and increased pro-
inflammatory cytokine levels, as well as reduced microglial phagocytic capacity [11]. Consequently, these 
triple transgenic mice show accelerated Aβ accumulation, and pharmacological upregulation of SR-A 
expression on mononuclear phagocytes increases Aβ clearance [12]. Interestingly, an association between 
sAPPα and Aβ clearance has also been demonstrated: sAPPα can interact with several partners participating 
in the Aβ clearance mechanism, such as SR-A and LRP1 in microglia, neurons, peripheral monocytes, and 
endothelial cells from the blood-brain barrier [8]. sAPPα enhances SR-A-mediated phagocytosis of Aβ by 
microglia and monocytes [8], and upregulates Aβ-degrading enzymes in microglia from APP/PS1ΔE9 mice, 
thereby reducing Aβ plaques [13]. However, involvement of sAPPα in astroglial Aβ clearance was not yet 
revealed. Our present work shows molecular mechanisms involved in enhanced Aβ removal by the 
mGlu3R/sAPPα system in astrocytes. 
 
2. Methods 
2.1. Animals. Wistar rat pups were obtained from the animal facility of INBIOMED Argentina. SR-A knockout 
and wild-type mice (129/ICR background) were kindly facilitated by their developer, Dr. Tatsuhiko Kodama 
(Research Center for Advanced Science and Technology, University of Tokyo, Japan)[14] and kept in the 
animal facility of the Neuroscience Department at School of Medicine, Pontificia Universidad Católica de 
Chile. Animals were housed in a temperature-regulated room with a 12 h light/dark cycle, with free access to 
food and water. Mice were genotypified after weaning.  
Experimental procedures were carried out in accordance with the National Institute of Health guidelines for 
the care and use of laboratory animals, with approval by the Committee on Ethics of the University of Buenos 
Aires Medical School (Res. 2068/2015) and the Pontificia Universidad Católica de Chile School of Medicine. 
All efforts were made to minimize animal suffering and to reduce the number of animals used. 
 
2.2. Astrocyte primary cultures. Astrocytes were obtained from cerebral cortices of male/female 1-2-day-old 
Wistar rat pups, as previously described [15]. Wild-type and SR-A knockout mice-derived cortical astrocyte 
cultures were prepared using the protocol of von Bernhardi and Eugenín [16]. Astrocyte cultures were 
maintained until the third week and were routinely close to 95% purity, as assessed by immunostaining 
with anti-GFAP monoclonal antibody (Millipore, MA, USA). Lack of SR-A in cultured astrocytes derived from 
SR-A knockout mice was previously demonstrated [11]. 
 
2.3. Treatments. After trypsinization from culture flasks, astrocytes were seeded on plaques or glass 
coverslips depending on the experimental assay and were treated with 0.1 μM LY379268 (mGlu3R agonist; 
Tocris Biosciences, Bristol, UK) or with 1-10 nM recombinant sAPPα (S9564 Sigma-Aldrich, Buenos Aires, 
Argentina) in DMEM supplemented with 2 mM L-glutamine, 50 mg/mL streptomycin and 50 U penicillin 
without serum for 3, or 24h as appropriate.  
 
2.4. Glial conditioned media (GCM) were obtained as previously described [9]. Briefly, 1x106 astrocytes were 
incubated with LY379268 or vehicle for 3h, conditioned medium was collected and either used as complete 
GCM or subjected to immunoprecipitation for sAPPα using anti-sAPPα (2B3) antibody (Immuno-Biological 
Laboratories Co., Ltd. MN, USA) as we previously described [9]. Supernatants were used as sAPPα-
immunodepleted GCM. Naïve astrocytes were then exposed to either complete control GCM, complete LY 
GCM, or sAPPα-immunodepleted LY GCM for 24h. Aβ uptake was determined after a further 24h of 
treatment with fluorescent Aβ. 
 
2.5. Aβ uptake quantification. After treatments, astrocytes (7x103 cells per glass coverslip) were incubated 
with 5 μM Aβ25-35 HiLyte-fluorTM Alexa488 (Anaspec Inc. CA, USA) for 24 h. Cells were fixed with 4% 
paraformaldehyde and identified by GFAP staining [9]. Nuclei were counterstained with DAPI. Uptake was 
analyzed under a fluorescence microscope (Axiophot, Carl Zeiss, Jena, Germany) and expressed as either the 
percentage of Aβ-positive astrocytes of total counted astrocytes (% phagocytic cells) or the fluorescence 
intensity per phagocytic cell calculated using ImageJ software (NIH). To determine the percentage of 
phagocytic cells, an average of 500 cells was counted per group for each independent experiment. To 
quantify fluorescence intensity per phagocytic cell, all phagocytic cells found in 15-20 random fields were 
analyzed per group for each independent experiment. 
Residual fluorescence in culture supernatants was also quantified using a Synergy HT microplate reader 
(Biotek, USA). 
 
2.6. Aβ uptake inhibition assay. Astrocytes were treated with LY379268 or sAPPα for 24h, then either the 
medium was replaced by fresh medium containing 5μM Aβ25-35 HiLyte fluor488 or Aβ25-35 HiLyte fluor488 was 
added directly to the supernatants containing the residual drugs. Aβ uptake was assayed after 24h. 
In another set of experiments, astrocytes were treated with vehicle or 1 nM sAPPα for 24h followed by 
medium replacement by either 5 μM fluor-Aβ or a mix containing 5 μM fluor-Aβ and 1 nM sAPPα (previously 
incubated at 37°C for 1h). After 24h, Aβ uptake was determined. Experimental groups were named as 
follows: 
Vehicle + fluor-Aβ: control group;  
sAPPα + fluor-Aβ: sAPPα group; 
sAPPα + fluor-Aβ/ sAPPα mix: sAPPα + sAPPα/Aβ group; 
Vehicle + fluor-Aβ/ sAPPα mix: DMEM + sAPPα/Aβ group. 
Also, astrocytes were treated with vehicle for 24h, then medium was replaced by anti-SR-A antibody (0.8 
μg/ml) to block SR-A for 1h, and then replaced by the fluor-Aβ/sAPPα mix (previously incubated at 37°C for 
1h) (‘DMEM + anti-SR-A + sAPPα/Aβ’ group). 
 
2.7. Reverse transcription and real-time PCR. Reverse transcription was performed from total astrocyte RNA 
as previously described [9]. Rat SR-A1 (NM_001191939.1), insulin-degrading enzyme (IDE, NM_013159.1) 
and neprilysine (NEP, NM_012608.2) genes were analyzed using the following PCR primer sets: SR-A 
forward 5’-CAG ACT CAA AAG CTG GCC TTC T-3’, SR-A reverse 5’-CGG TTG CCA TGC TGA AGT T-3’, IDE 
forward 5’-CGC ACA GAG CAG TGG TAT GG-3’, IDE reverse 5’-GAA TGA CGT CCT CTG GGA TAG C-3’, NEP 
forward 5’-TGC AGC CCC CAT TCT TTA GT-3’, NEP reverse 5’-CGA TGC CCC CAT AGT TCA AT-3’. 
HPRT was used as endogenous control (HPRT forward 5’-CTCATGGACTGATTATGGACAGGAC-3’, HPRT 
reverse 5’-GCAGGTCAGCAAAGAACTTATAGCC-3’). PCR amplifications were done in a StepOne_ Real-Time 
PCR System (Applied Biosystems, Life Technologies Co, CA, USA) and PCR reactions were set up to a final 
volume of 16 μL containing 4 μL of cDNA, 200 nM primers (for SR-A/HPRT) or 250 nM primers (for 
IDE/HPRT) or 350 nM (for NEP), and SYBR Select Master Mix (Applied Biosystem). PCR conditions were 
UDG activation at 50°C for 2 min and denaturation at 95°C for 2 min, followed by 40 cycles of 95°C for 15 s 
and 60°C for 1 min. PCR product specificity was verified by a melting curve analysis. No-RT controls omitted 
the reverse transcriptase enzyme, and no-template controls were performed by addition of nuclease-free 
water instead of cDNA. Levels of SR-A, IDE, and NEP expression were normalized to the endogenous control 
gene HPRT and analyzed with Step-One Software (Applied Biosystems) using the comparative ∆∆Ct method. 
Data were reported as RQ mean of 2-4 biological replicates (with 3 technical replicates each) ± SE. 
 
2.8. Western blot. Astrocyte cultures (1x106 cells) were treated with LY379268 or recombinant sAPPα for 
24h. Total protein extracts were obtained after lysis with 50 mM Tris-HCl pH 7.4, 1 mM EDTA, 150 mM NaCl, 
1% NP-40, and protease inhibitors (2 mM PMSF and protein inhibitor cocktail Sigma-Aldrich) followed by 
sonication and centrifugation at 12,000 rpm for 30 min. Protein concentration in supernatants was 
determined by the Bradford method (BioRad Laboratories, CA, USA) using bovine serum albumin as 
standard. Fifty micrograms of protein were size-fractionated in 8% sodium dodecyl sulfate (SDS)-
polyacrilamide gel. Proteins were electrotransferred to a polyvinylidene difluoride membrane and blots 
were blocked in 1% or 5% nonfat dry milk-TBS-0.1% Tween 20 for 1h and incubated overnight at 4°C with 
1:100 anti-SR-A (sc-1661396 Santa Cruz Biotechnology, TX, USA) or 1:200 anti-β-actin (sc-47778 Santa Cruz 
Biotechnology) in 1% or 5% milk-TBS-0.1% Tween 20. After 1h incubation with the corresponding 
biotinylated secondary antibodies (Millipore Co., MA, USA) and 1h incubation with Streptavidin-peroxidase 
(Thermo Fisher, Buenos Aires, Argentina), immunoreactivity was detected by enhanced chemiluminescence 
(Bio-Lumina, Productos Bio-Lógicos, Buenos Aires, Argentina). SR-A and β-actin expression were analyzed 
on the same membrane after stripping. Bands were analyzed using SCION Image software. Results were 
normalized to the internal control and expressed as arbitrary units relative to the corresponding controls. 
 
2.9. Co-immunoprecipitation assays. Total protein extracts (100 μg) from cultured astrocytes were diluted in 
lysis buffer (50 mM Tris-HCl pH 7.5, 140 mM NaCl, 0.1% NP-40, 1 mM PMSF, 200 μM Na3VO4, 1 mM NaF, and 
protease inhibitors cocktail). After preclearing with protein A/G agarose at 4°C for 2h to reduce non-specific 
adsorption, proteins were incubated with 1-2 μg anti-SR-A (sc-1661396 Santa Cruz Biotechnology) at 4°C 
with continuous shaking overnight. Immune complexes were precipitated using 20 μl protein A/G 
agarose/tube at 4°C for 2h. After washing the pellet 3 times with washing buffer (50 mM Tris-HCl pH 7.5, 
250 mM NaCl, 0.1% NP-40, 1 mM PMSF, 200 μM Na3VO4, 1 mM NaF, and protease inhibitors cocktail), pellets 
were resuspended in 25 μl sample buffer containing β-mercaptoethanol. coIP proteins were loaded onto 8% 
SDS-PAGE and transferred to PVDF membranes, which were blocked in 5% or 1% nonfat dry milk-TBS-0.1% 
Tween 20 and incubated overnight at 4°C with 1:50 anti-sAPPα (#11088, clone 2B3, Immuno-Biological 
Laboratories Co., Ltd.) or 1:100 anti-SR-A (Santa Cruz Biotechnology) in 5% or 1% milk-TBS-0.1% Tween 
20, respectively. After 1h incubation with the biotinylated secondary antibody (Millipore Co.) and 1h 
incubation with Streptavidin-peroxidase (Thermo Fisher), immunoreactivity was detected by enhanced 
chemiluminescence (Bio-Lumina, Productos Bio-Lógicos). sAPPα and SR-A expression was analyzed on the 
same membrane after stripping. In parallel, total protein extracts (50 μg) were loaded onto the same SDS-
PAGE in order to confirm the presence of SR-A in each sample (input). Since sAPPα was not detected in total 
protein extracts from astrocytes (input), we used 2 μg recombinant sAPPα as a positive control for sAPPα 
detection. As a negative control, IP was performed using an irrelevant, same-isotype, and same-species 
antibody. 
Since both SR-A and sAPPα antibodies were generated in mice, we detected in the western blot two bands 
corresponding to mouse IgG aside from the specific bands for SR-A and sAPPα.  
 
2.10. Immunofluorescence. Astrocytes (7x103 cells/coverslip) were fixed with 4% paraformaldehyde, blocked 
in PBS plus 10% donkey and goat serum, and incubated with primary antibodies diluted in PBS plus 1% 
donkey and goat serum overnight at 4°C as following: 1:100 anti-SR-A (ab123946, Abcam, Cambridge, UK) 
and 1:25 anti-sAPPα (Immuno-Biological Laboratories). After washing, cells were labeled with donkey anti-
mouse and goat anti-rabbit IgG conjugated with Cy3 or FITC and counterstained with DAPI. Images were 
obtained using a fluorescence microscope (Axiophot, Carl Zeiss, Jena, Germany) at 400X magnification.  
 
2.11. MTT assays. Astrocytes (4x104 cells/well) were treated with either fibrillar (Aβ25-35 incubated at 37°C 
for 3 days) or non-fibrillar Aβ25-35 (25 μM, Sigma-Aldrich) in the presence or absence of recombinant sAPPα 
(1-10 nM) for 24h. Metabolic activity of viable cells was measured by the 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) assay as previously described [17]. 
 
3. Results 
3.1. Astroglial SR-A levels increased in response to mGlu3R activation and sAPPα 
Considering that mGlu3R activation increases Aβ clearance by astrocytes [9], and SR-A plays a main role in 
the decline in Aβ removal during AD [11], we aimed to investigate SR-A involvement in the aforementioned 
mGlu3R effect. First, we assessed whether SR-A levels are modified after mGlu3R activation. Both mRNA and 
protein levels of SR-A increased after astrocyte treatment with the mGlu3R agonist LY379268 (0.1 μM, 
Figure 1a-b). 
Since sAPPα has been linked to enhanced SR-A -mediated Aβ uptake by microglial cells [8], we next studied 
the effect of recombinant sAPPα on astroglial SR-A levels. Although mRNA levels remained unchanged 
(Figure 1a), SR-A protein expression was significantly increased by 1 nM sAPPα (Figure 1b).  
 
Figure 1  
 
3.2. Release of sAPPα after mGlu3R activation mediated Aβ clearance 
sAPPα involvement in mGlu3R-induced Aβ uptake by astrocytes was further demonstrated by treating naïve 
astrocytes with conditioned medium (GCM) from astrocytes treated with LY379268 (LY-GCM). Complete LY-
GCM increased the uptake of fluorescently-labeled Aβ25-35 by naïve astrocytes by 60% compared to complete 
control-GCM (Figure 1c). However, when LY-GCM was immunodepleted of sAPPα, the aforementioned 
stimulatory effect was lost (Figure 1c), evidencing an autocrine or paracrine role of sAPPα in the mGlu3R-
induced Aβ uptake by astrocytes. Although an effect of remnant LY379268 in the GCM on naïve astrocytes 
could be possible in these experiments, the fact that sAPPα depletion from LY-GCM completely inhibited the 
LY-GCM-induced Aβ uptake allows us to discard this possibility. Moreover, we previously reported that LY-
GCM subjected to IP in absence of anti-sAPPα antibody did not modify the effect of complete LY-GCM on 
neuron viability [9], thereby discarding any technical artifact of immunoprecipitation in the observed 
biological effects. 
As seen earlier for Aβ1-42 [18, 19], Aβ25-35 was localized post engulfment in both astrocyte cytoplasm and 
nucleus (Figure 1d).  
 
 3.3. SR-A involvement in mGlu3R- and sAPPα-induced Aβ uptake 
To define the participation of SR-A in mGlu3R-induced Aβ uptake, fluorescently-labeled Aβ25-35 phagocytosis 
was measured in primary cultured astrocytes from wild-type and SR-A knockout mice. After treating 
astrocytes with LY379628 (0.1 μM) or sAPPα (1 or 10 nM), medium was replaced by fresh medium 
containing 5 μM Aβ25-35 HiLyte fluor488. After 24h, Aβ uptake was determined by fluorescent microscopy and 
expressed as the percentage of phagocytic cells in the total counted cells. Whereas all treatments increased 
Aβ phagocytosis in wild-type astrocytes, none affected Aβ uptake in SR-A-deficient astrocytes (Figure 2a). 




Quantification of intracellular fluorescence in phagocytic cells revealed increased fluorescence intensity in 
LY379268 and sAPPα groups for wild-type astrocytes (Figure 2b). As expected, none of the treatments 
affected intracellular fluorescence levels in SR-A-deficient astrocytes (Figure 2b). Therefore, LY379268- and 
sAPPα-induced increase of Aβ accumulation in astrocytes required the presence of SR-A, since it was 
abolished in SR-A deficient cells, indicating that this process was most likely mediated by SR-A.  
We also measured expression of the two most important Aβ degrading enzymes in wild-type astrocytes: 
insulin-degrading enzyme (IDE) and neprilysin (NEP). Surprisingly, neither LY379268 nor sAPPα modified 
mRNA levels of these catalytic enzymes (Figure 2c-d). Therefore, mGlu3R/sAPPα pathway might promote Aβ 
uptake and accumulation into astrocytes rather than its intracellular degradation. 
 
3.4. The presence of residual sAPPα in supernatants inhibited Aβ uptake 
An interesting and surprising finding emerged when we compared results from phagocytosis assays 
performed by two different approaches: first, as described in Figure 2, after treating astrocytes with 
LY379628 or sAPPα, medium was completely replaced by fresh medium containing fluorescent Aβ, and Aβ 
uptake was determined 24h later (Figure 3a). Alternatively, after treating astrocytes with LY379628 or 
sAPPα, fluorescent Aβ was added to the culture medium containing incubation drugs (Figure 3b). In both 
cases, the control group was set as 100% and data relativized to 100%. 
The stimulatory effect of sAPPα on Aβ uptake observed when the medium was replaced (Figure 3a) was 
abolished when Aβ was added to the incubation medium with drugs (Figure 3b). The stimulatory effect of 
LY379268 when medium was replaced (an approximately 25% increase in phagocytic cells, Figure 3a) was 
lowered to around 10% when Aβ was added to the incubation medium (Figure 3b).  
Considering that sAPPα can interact with SR-A [20] as well as with Aβ [21], one possible explanation for our 
observations could be that, in the second case, residual sAPPα present in the medium (both recombinant and  
endogenous sAPPα released in response to LY379268) was binding to Aβ and sequestering it, thereby 




In order to address this issue, we designed an alternative experimental scheme (Figure 4a): astrocytes were 
incubated with vehicle (1st and 4th column) or sAPPα (2nd and 3rd column) for 24h; then, supernatant was 
replaced by fluorescent Aβ (1st and 2nd column) or by a mixture of sAPPα + fluorescent Aβ previously 
incubated for 1h at 37°C to allow for their interaction (3rd and 4th column), as described by Darlington et al. 
[21]. After a further 24h, Aβ uptake was analyzed. Our results show that Aβ/sAPPα complexes (obtained 
after in vitro heterodimerization) inhibited Aβ uptake in astrocytes pre-treated with sAPPα (Figure 4a-b, 3rd 
column) versus the sAPPα group (Figure 4a-b, 2nd column). However, when astrocytes were not pre-treated 
with sAPPα (therefore presumably not saturated SR-A) the mentioned inhibitory effect of Aβ/sAPPα 
complexes was reversed (Figure 4a-b, 4th column). On the contrary, Aβ/sAPPα complexes were unable to 
change Aβ uptake when SR-A was blocked with an anti-SR-A antibody (Figure 4a-b, 5th column). Altogether, 
these results indicate that free and SR-A-associated sAPPα may compete for Aβ binding, further suggesting 




3.5. sAPPα/SR-A dimerization 
Interaction between sAPPα and SR-A at the astrocyte’s membrane was studied. Co-immunoprecipitation (IP) 
assays from protein lysates were performed using anti-SR-A antibody for IP followed by immunoblot (IB) for 
sAPPα (Figure 5a). We detected a 75 KDa-band corresponding to sAPPα in SR-A-precipitated samples (red 
arrowhead), which evidences direct interaction between these proteins. Since sAPPα is undetectable in the 
input sample (cellular lysates), recombinant sAPPα was run as a positive control. As an IP control, the same 
membrane was stripped and assayed by immunoblot for SR-A (Figure 5b). The specific band for SR-A (white 
arrowhead) was detected in immunoprecipitated samples as well as in the input. In the negative control the 
same unspecific band was observed in the two IB. 
 
Figure 5  
 
We also detected SR-A and sAPPα in non-permeabilized astrocytes by immunofluorescence, indicating that 
these proteins are associated with the plasma membrane (Figure 5c-e). Using double immunofluorescence 
labeling, we observed that SR-A and sAPPα were closely localized in the astrocyte plasma membrane (Figure 
5c-d). A punctuate staining pattern seen for sAPPα coincides with the SR-A staining pattern in several 
regions of the plasma membrane of most cells. This circumscribed staining pattern is coherent with 
previously reported localization of sAPPα in membrane microdomains or rafts in other cell types [22, 23].  
 
3.6. Astrocyte viability was not affected by sAPPα 
To investigate whether sAPPα can influence other cellular processes, beyond its particular 
autocrine/paracrine role in Aβ uptake by astrocytes, we analyzed sAPPα effect on astrocyte viability after Aβ 
exposure. Cell viability was significantly decreased by 25 μM Aβ25-35 (Figure 6a-b). The detrimental effect of 
Aβ on cell viability was independent of its aggregation status and was not modified by either 1 or 10 nM 
sAPPα (Figure 6a-b). sAPPα had no effect per se on astroglial viability (Figure 6a-b). Therefore, 
autocrine/paracrine action of sAPPα in astrocytes appears to affect Aβ elimination, but does not protect cells 





In the field of AD, much interest is focused on Aβ toxicity, and most proposed therapies aim to mitigate Aβ 
production. However, it is likely that parallel deficiency in non-amyloidogenic cleavage (and consequently, 
ineffective sAPPα release) has a major impact on AD onset/progression. Also, astrocyte neuroprotective 
functions may have major therapeutic relevance for AD. In fact, glial cell dysregulation has been suggested as 
a possible cause of AD [11, 24]. In the present study, we demonstrated that sAPPα produced by astrocytes in 
response to mGlu3R activation could act in a paracrine or autocrine fashion to stimulate Aβ uptake by 
astrocytes. We also showed that sAPPα- and mGlu3R-induced Aβ internalization by astrocytes depends on 
SR-A participation; we further suggest that sAPPα might dimerize with SR-A to enhance Aβ uptake. These 
results complement our previous work showing that astrocyte-derived sAPPα released after mGlu3R 
activation prevents hippocampal neuron death induced by Aβ [9], and contribute to consolidate the 
mGlu3R/sAPPα pathway as a relevant therapeutic target for AD. 
Whereas Aβ production is accelerated in many familial forms of early-onset AD, increasing evidence 
indicates that impaired clearance of Aβ is more evident in late-onset AD [25]. Despite a long delay in 
recognizing astrocyte phagocytic potential compared to microglia or macrophages, the participation of 
plaque-associated astrocytes in Aβ elimination from AD brains is now well known. Unlike microglia, a 
fundamental singularity of astrocytes in the Aβ degradation process is their ability to internalize and 
degrade Aβ without requiring pre- or co-stimulation by cytokines [26]. Several surface mediators have been 
suggested as putative Aβ-binding partners in astrocytes, including SR. However, divergent evidence has been 
presented on SR expression in glial cells. Whether studies are made using newborn or adult glial cells, 
plaque-associated (or not) cells, under certain pathophysiological conditions, or in knockout animal models 
are all factors that can affect the expression pattern and/or activity of SR in astrocytes and microglia, or even 
modify the identity of the SR involved in Aβ elimination. Frenkel, et al. [12] showed that SR-A deficiency 
clearly impairs Aβ clearance and reduces NEP and IDE expression in the APP/PS1 AD model. Concordantly, 
SR-A mediates oligomeric Aβ internalization and further lysosomal degradation by cathepsin B in microglia 
[27]. A reduction in hippocampal SR-A expression with age has also been reported, appearing earlier in 
APP/PS1 mice than in wild-type animals [11]. These changes were attributed mainly to altered expression of 
SR-A in microglial cells rather than in astrocytes and were accompanied by impaired microglial phagocytic 
activity, impaired working memory, and higher mortality rate [11]. Iram, et al. [28] demonstrated that adult 
astrocytes isolated from old 5xFAD mice show impaired Aβ clearance and that incubation of Aβ with C1q 
enhances phagocytic activity, which was suggested to depend on SR-B1, not SR-A. In contrast, our present 
results show that both mGlu3R activation as well as recombinant sAPPα induced SR-A protein expression 
and SR-A-dependent Aβ uptake. However, these findings refer to mGlu3R- and/or sAPPα-induced Aβ uptake 
by postnatal astrocytes, whereas Iram’s experiments reflect changes in old, AD mice-derived astrocytes. 
Considering the decline in SR-A expression with age, it is likely that a compensatory increase in SR-B1 levels 
accounts for C1q-stimulated Aβ uptake, as suggested by Husemann, et al. [29]. However, our results do not 
support a redundancy mechanism scenario since SR-A depletion completely blocked mGlu3R- and sAPPα-
induced Aβ phagocytosis. Our present results further show that SR-A-deficient astrocytes retained their 
basal phagocytic capacity although they lacked response to LY379268 or sAPPα stimuli, a finding that might 
tally with reported lack of SR-A involvement in basal Aβ phagocytosis. Therefore, we are hereby 
characterizing a pathway that might be specific for mGlu3R/sAPPα-stimulated Aβ clearance. 
The therapeutic potential of sAPPα has been highlighted since the discovery of its neurotrophic and 
neuroprotective actions on neural cells (reviewed in [8]). Aside from its direct neurotrophic action, sAPPα 
can allosterically bind and inhibit β-secretase, leading to reduced Aβ synthesis [30, 31]. sAPPα also reduces 
tau hyperphosphorylation and GSK3β activity in neural cells and in the APP/PS1 model [32], and can 
improve cognition (reviewed in [8]). sAPPα enhances SR-A -mediated Aβ phagocytosis by microglia and 
monocytes [21], and sAPPα overexpression in APP/PS1∆E9 mice rescued structural, electrophysiological, 
and behavioral deficits in these mice through microglial activation, and increased Aβ clearance [13]. 
However, although we know that astrocytes can also secrete sAPPα, which then enhances neuron survival [8, 
9], autocrine or paracrine effects of this peptide on astroglial cells have not been exhaustively explored. We 
show here for the first time that sAPPα promotes Aβ clearance by cultured astrocytes. Moreover, sAPPα 
release by astrocytes after mGlu3R stimulation is required for mGlu3R-induced astroglial Aβ uptake, since 
sAPPα-depleted conditioned medium from LY-treated astrocytes did not induce Aβ uptake by naïve 
astrocytes, as did complete LY-GCM. This result was corroborated by using recombinant sAPPα, which was 
also able to improve Aβ uptake by both rat and mouse astrocytes. After this uptake, we observed an 
accumulation of Aβ within astrocytes, indicated by increased intracellular fluorescence in the phagocytic 
cells, and found no changes in mRNA levels of the two most important glial Aβ degrading enzymes, IDE and 
NEP. Concordant with these observations, Söllvander, et al. [33] demonstrated that astrocytes do not 
degrade but instead store engulfed Aβ protofibrils, since protofibrils persist for a long time in the cytoplasm 
of cultured astrocytes.  
Better understanding of sAPPα functions and binding partners is needed in order to comprehend its 
neuroprotective role. Interestingly, Hoffmann, et al. [22] found that sAPP binding at the cell surface is 
saturable, specific, and dependent on cell differentiation, occurring in patches or microdomains. Signaling 
transduction after sAPPα binding to cell membranes should be mediated by a receptor protein that has yet 
to be univocally identified. Also, it is known that phagocytosis of Aβ by human astrocytes may depend on Aβ 
conformation as well as on its association with several amyloid-associated proteins [34]. Our present results 
suggest that SR-A binds sAPPα and that this complex, in turn, binds Aβ to allow for Aβ clearance. 
Alternatively, sAPPα could associate with Aβ and then bind to SR-A to promote Aβ phagocytosis. However, 
sAPPα/Aβ complexes might be unable to attach to the cell when SR-A are pre-occupied by sAPPα. We further 
demonstrated sAPPα-SR-A interaction by coIP assay as well as by double labeled immunofluorescence, 
which revealed physical interaction between these proteins. Regarding immunofluorescence, despite 
ubiquitous APP expression, we were still able to detect sAPPα specifically after using clone 2B3 sAPPα 
antibody, which does not bind full length APP or sAPPβ, as stated by the manufacturer. Altogether, our data 
support the hypothesis that sAPPα functions as a carrier that reinforces binding of Aβ to SR-A, thereby 
enhancing Aβ attachment and uptake by astrocytes. Previous evidence agrees with this hypothesis. Aβ is 
able to bind APP-derived peptides [21, 35, 36]. All SR-A ligands are polyanions, and sAPPα has a negatively 
charged region thought to be responsible for binding to SR-A [20]. Providing strong support for our findings, 
Darlington, et al. [21] have shown that, whereas aged monocytes display ineffective phagocytosis of Aβ, 
pretreatment of aged monocytes with sAPPα restores their phagocytic potential. They also suggested that 
sAPPα could form a heterodimer with Aβ, thereby promoting binding of these heterodimers to monocyte 
scavenger receptors and enhancing Aβ clearance. Similar to our hypothesis, results from Zhang, et al. [37] 
indicate that heterodimerization between Aβ1–42 and peptide XD4 may be a prerequisite for enhanced 
internalization of Aβ1–42 by microglia and, further, that Aβ1–42 may be internalized as Aβ1–42–XD4 complex. 
Moreover, XD4-induced Aβ1–42 phagocytosis by microglia is dependent on SR-A.  
Finally, we show here that Aβ25-35 (the shortest Aβ peptide displaying neurotoxicity [38]) exerted a toxic 
effect on cultured astrocytes, as previously reported [19]. This effect was independent of the state of 
aggregation of the peptide, since both fibrillar and non fibrillar Aβ25-35 induced similar levels of astrocyte 
death. In both cases, recombinant sAPPα had no effect on astrocyte viability, a finding that contrasts with the 
reported pro-survival effect of sAPPα on hippocampal neurons [9].  
 
5. Conclusion 
Growing knowledge of astroglial involvement in Aβ plaque clearance encourages research oriented towards 
restoring Aβ uptake mechanisms in astrocytes as promising therapy for AD. Although microglia is widely 
accepted as the star phagocytes in brain, microglial functions are also known to be impaired in aging/AD 
models. Therefore, conservation or stimulation of astroglial function to potentially compensate for the loss 
of microglial phagocytic action merits research efforts focused on clearing Aβ from AD brains. Our present 
results show that the mGlu3R/sAPPα pathway stimulates Aβ clearance by astrocytes in an SR-A-dependent 
fashion. We also suggest a double binding of sAPPα to SR-A and Aβ as the mechanism underlying Aβ 
clearance enhancement by mGlu3R and sAPPα. However, we must be cautious when extrapolating results 
obtained from neonatal astrocytes to adult/aged astrocytes, since developmental changes in SR expression 
are broadly reported. 
Although sAPPα offers great therapeutic potential, it is too large to cross the BBB [8]. Another predictable 
way to increase sAPPα levels in the brain would be to increase α-secretase activity, but this option involves 
severe secondary alterations in alternative α-secretases substrates. Therefore, all evidence favors selective 
mGlu3R activation as a therapeutic target for AD, since its agonists can cross the BBB, while also exerting 
several neuroprotective actions and ensuring endogenous release of sAPPα from astrocytes.  
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9. Legends  
Figure 1. sAPPα involvement in Aβ clearance by astrocytes. Rat primary astrocyte cultures were 
incubated with the mGlu3R agonist LY379268 (0.1 μM) or recombinant sAPPα (1 nM) for 24h and mRNA (a) 
or protein (b) levels of the class-A scavenger receptor (SR-A) were determined by real-time RT-PCR or 
western blot, respectively. Data were expressed as mean ± SE of RQ (a) or of arbitrary units relative to the 
control group (b) from 4 independent experiments. *p<0.05 versus control group (Student’s t test). (c) 
Astrocytes were treated with vehicle or LY379268 for 3h, then glial conditioned medium (GCM) was 
collected and half volume subjected to sAPPα immunodepletion using an anti-sAPPα antibody and protein 
A/G agarose. Naïve astrocytes were incubated for 24h with complete control GCM, complete LY GCM, or 
sAPPα-immunodepleted LY GCM, followed by a further 24h treatment with 5 μM Aβ25-35 HiLyte fluor488. Aβ 
uptake was determined under a fluorescence microscope (Zeiss 40x objective) and expressed as the 
percentage of phagocytic cells of total counted cells. Data were shown as mean percentage ± SE from 4 
independent experiments. *p<0.05 versus complete control GCM group (One way ANOVA followed by 
Bonferroni’s test). A representative image is shown in (d). 
 
Figure 2. mGlu3R- and sAPPα-induced Aβ uptake by astrocytes depend on SR-A. Primary astrocyte 
cultures derived from wild-type (pink bars) or SR-A knockout (yellow bars) mice were incubated with 0.1 
μM LY379268 or 1-10 nM recombinant sAPPα for 24h. Then medium was replaced by fresh medium 
containing 5 μM Aβ25-35 HiLyte fluor488 for a further 24h. Aβ uptake was determined by fluorescent 
microscopy and expressed as the percentage of phagocytic cells of total counted cells (a). Intracellular 
fluorescence intensity per phagocytic cell was quantified using ImageJ (b). Bars represent the mean ± SE 
from 3-4 independent experiments (*p<0.05, **p<0.01, ***p<0.001 versus control of same genotype, Two 
way ANOVA followed by Bonferroni’s test). (c and d) Rat primary astrocyte cultures were incubated with 0.1 
μM LY379268 or 1 nM recombinant sAPPα for 24h and mRNA levels of IDE (c) and NEP (d) were determined 
by real-time RT-PCR. Data were expressed as RQ mean ± SE from 2 independent experiments. 
 
Figure 3. Residual sAPPα in supernatants inhibits Aβ uptake by astrocytes. Astrocytes were treated 
with vehicle, LY379268, or sAPPα for 24h and then either the medium was replaced by fresh medium 
containing 5 μM Aβ25-35 HiLyte fluor488 (a) or else the Aβ25-35 HiLyte fluor488 was added directly to the culture 
media containing the drugs (b). After 24h, Aβ uptake was determined and the percentage of phagocytic cells 
was expressed relative to the corresponding control group, which was set as 100%. *p<0.05, **p<0.01 
versus control group (Student’s t test, n=3 independent experiments). A hypothesis to explain the results is 
represented in (c): if SR-A at the cell membrane binds sAPPα and this, in turn, binds to Aβ, then the presence 
of free sAPPα in the culture media would compete with SR-A-bound sAPPα for Aβ binding, thereby avoiding 
Aβ clearance. 
 
Figure 4. sAPPα interacts with Aβ and SR-A to enhance Aβ uptake. (a) Schematic representation of the 
experimental design:  
‘Control’ group: astrocytes were treated with vehicle for 24h. Then, medium was replaced by Aβ25-35 HiLyte 
fluor488 for a further 24h; first column in (b) 
‘sAPPα’ group: astrocytes were treated with sAPPα for 24h. Then, medium was replaced by Aβ25-35 HiLyte 
fluor488 for a further 24h; second column in (b) 
‘sAPPα + sAPPα/Aβ’ group: astrocytes were treated with sAPPα for 24h. Then, medium was replaced by 
fresh medium containing Aβ25-35 HiLyte fluor488 and sAPPα (previously incubated at 37°C for 1h) for a further 
24h; third column in (b) 
‘DMEM + sAPPα/Aβ’ group: astrocytes were treated with vehicle for 24h. Then, medium was replaced by 
fresh medium containing Aβ25-35 HiLyte fluor488 and sAPPα (previously incubated at 37°C for 1h) for a further 
24h; fourth column in (b) 
‘DMEM + anti-SR-A + sAPPα/Aβ’ group: astrocytes were treated with vehicle for 24h. Then, medium was 
replaced by anti-SR-A antibody (0.8 μg/ml) to block SR-A for 1h, then medium was replaced by fresh 
medium containing Aβ25-35 HiLyte fluor488 and sAPPα (previously incubated at 37°C for 1h) for a further 24h; 
fifth column in (b). 
In (b) Aβ uptake was determined and expressed as the percentage of phagocytic cells. Bars represent the 
mean percentage ± SE from 4 independent experiments. (*p<0.05 versus control group; ^p<0.05 versus 
‘sAPPα + sAPPα/Aβ’ group, One way ANOVA followed by Bonferroni’s test) 
 
Figure 5. sAPPα-SR-A binding. Protein lysates (100 μg) from astrocytes were immunoprecipitated (IP) 
using 1 or 2 μg of anti-SR-A antibody and protein A/G agarose and analyzed by immunoblot (IB) using anti-
sAPPα antibody (a) or anti-SR-A antibody (b). Positive bands are indicated by red (sAPPα) or white (SR-A) 
arrowheads. Neg.: negative control (lysates immunoprecipitated with 2 μg of an irrelevant antibody; the 
same unspecific band was detected in the two blots). Input: complete protein lysate without IP; sAPPα was 
undetectable in cell lysates. As positive control, 2 μg of recombinant (rec) sAPPα were analyzed by western 
blot. sAPPα and SR-A expression was analyzed on the same membrane after stripping. Since both SR-A and 
sAPPα antibodies were generated in mice, bands corresponding to IgG’s are present in the IB’s. 
The same result was obtained in 3 independent experiments.  
(c) Immunofluorescence for SR-A and sAPPα in primary cultured astrocytes was performed without 
permeabilizing membranes in order to detect membrane-associated peptides (Zeiss 40x objective). (d) 
Merging was done using Adobe Photoshop CS. Higher magnification of inset is shown on the right. (e) 
Negative control: immunofluorescence in absence of primary antibodies. 
 
Figure 6. The detrimental effect of Aβ on astrocyte viability is not prevented by sAPPα. Astrocytes 
were incubated with 25 μM Aβ25-35 either as fibrils (pre-aggregated Aβ at 37°C for 3 days) (a) or without pre-
aggregation (b) in the presence or absence of sAPPα (1-10 nM) for 24h. Cell viability was determined by the 
MTT assay. ***p<0.001 versus control group (One-way ANOVA followed by Bonferroni’s test, n=8 
determinations from one experiment representative of two independent ones). 
Highlights 
• sAPPα released by astrocytes after mGlu3R stimulation induces Aβ uptake 
• mGlu3R and sAPPα-induced Aβ clearance by astrocytes depend on SR-A participation 
• Astrocytes appear to accumulate rather than degrade phagocyted Aβ 
• sAPPα can dimerize with SR-A at the astroglial surface 
• sAPPα might serve as a carrier for Aβ to enhance SR-A-mediated Aβ clearance 
